IDH1 and glioblastoma: However, for human IDH-wildtype glioblastoma (huGBM)—a common and aggressive brain cancer typified by a median survival of just 14-22 months depending on MGMT promoter methylation status (2, 3)—the near-uniform negative results of single-agent immune checkpoint blockade (ICB) clinical trials have been disappointing (4–6).